Stock comparison
Artivion
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AORT
Artivion
Market cap
$1.09B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AORT | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 35D | 70B | HAE |
| Benjamin Graham | 63D | 85A | HAE |
| Philip Fisher | 48D | 60C | HAE |
| Peter Lynch | 32F | 54C | HAE |
| Joel Greenblatt | 41D | 31F | AORT |
| Charlie Munger | 43D | 54D | HAE |
| Terry Smith | 36D | 55D | HAE |
Side-by-side metrics
| Metric | AORT | HAE |
|---|---|---|
| Market cap | $1.09B | $2.98B |
| P/E (TTM) | 93.6x | 24.8x |
| EV/EBIT | 48.9x | 14.1x |
| ROIC (TTM) | 3.0% | 8.37% |
| Gross margin | 62.94% | 55.74% |
| Net margin | 2.55% | 7.29% |
| Revenue CAGR 5y | 10.24% | 7.65% |
| EPS CAGR 5y | - | 24.62% |
| Debt / Equity | 0.6x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AORT leads on
- Debt / Equity0.6xvs 1.5x+63%
- Revenue CAGR 5y10.24%vs 7.65%+25%
- Gross margin62.94%vs 55.74%+11%
HAE leads on
- P/E (TTM)24.8xvs 93.6x+73%
- EV/EBIT14.1xvs 48.9x+71%
- Net margin7.29%vs 2.55%+65%
- ROIC (TTM)8.37%vs 3.0%+64%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.